Longeveron Inc. LGVN
Longeveron Inc. (Nasdaq: LGVN) is a cardio-renal-metabolic drug developer. Its lead program, laromestrocel (Lomecel-B; allogeneic mesenchymal stem cell therapy), is in Phase 2 for Hypoplastic Left Heart Syndrome (ELPIS II).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| laromestrocel - ELPIS II (Phase 2b) | Hypoplastic Left Heart Syndrome | cell therapy | Phase 2 |
| laromestrocel - planned Phase 2/3 adaptive trial | Mild Alzheimer's disease | cell therapy | Phase 2 |
| laromestrocel | Aging-related frailty | cell therapy | Phase 2 |
| laromestrocel - planned Phase 2 registrational trial | Pediatric dilated cardiomyopathy | cell therapy | Pre-clinical |
Recent results and decisions
- Oct 26, 2026mixed ELPIS II trial did not meet primary endpoint (RVEF) but achieved statistical significance in pre-specified secondary endpoint (MACE) with favorable clinical outcomes.
The ELPIS II trial did not meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction (RVEF) at Month 12.
Filing - Sep 16, 2026missed ELPIS II missed primary endpoint of RVEF change at Month 12 (LS mean difference -0.7 points, 95% CI -7.3 to 5.9, p=0.8336); exploratory MACE ~31% fewer events (12 vs 19) not significant.
The ELPIS II trial did not meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction (RVEF) at Month 12.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.